Squamous lung carcinoma data add further weight to promise of Oncolytics' Reolysin
This article was originally published in Scrip
Executive Summary
The day after Oncolytics Biotech said it would split the first Phase III clinical trial for Reolysin - the Canadian company's proprietary formulation of human reovirus - into two separate patient groups, it announced positive interim results from a Phase II trial in squamous cell carcinoma of the lung (SCCLC) that justified continuation of the 55-patient study.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.